Search results
Contralateral breast cancer and tumor recurrence in BRCA1/2 carriers and non-carriers at a high risk of hereditary breast cancer after bilateral mastectomy. Marta Allué Cabañuza, , María Domingo Bretónb, Jorge Chóliz Ezquerroc, María Dolores Arribas del Amoa, Antonio Tomás Güemes Sánchezd.
BRCA1/2. Abstract. Introduction: There is no consensus on the indications for contralateral mastectomy (CM) in patients diagnosed with unilateral breast cancer without germline BRCA1/2 mutations. Prior studies have identified some factors that could influence decision-making.
RESUMEN. Se ha observado una tendencia en los últimos años a un incremento de la mastectomía profiláctica contralateral en pacientes con diagnóstico de cáncer de mama unilateral, argumentada como cirugía reductora de riesgo y de prevención del desarrollo futuro de cáncer de mama en la mama sana.
A cancer in the contralateral breast in a woman with a previous or synchronous breast cancer is typically considered to be an independent primary tumor. Emerging evidence suggests that in a small subset of these cases the second tumor represents a metastasis.
1 gru 2020 · Resumen. Introducción. La mastectomía contralateral profiláctica (MCP) reduce el riesgo de cáncer contralateral en al menos un 90%. Además, las portadoras de mutación BRCA tienen mayor riesgo de recurrencia ipsilateral y de un segundo tumor primario.
21 paź 2022 · Prediction of contralateral breast cancer (CBC) risk is challenging due to moderate performances of the known risk factors. We aimed to improve our previous risk prediction model (PredictCBC) by updated follow-up and including additional risk factors.
17 lut 2021 · Estimates of contralateral breast cancer (CBC) risk in the modern treatment era by year of diagnosis and characteristics of the first breast cancer are needed to assess the impact of recent advances in breast cancer treatment and inform clinical decision making.
